Promising combo aims to tame relapsed childhood cancers
NCT ID NCT02574728
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a daily combination of sirolimus, celecoxib, and low-dose chemotherapy in 46 children whose solid or brain tumors have returned or not responded to standard treatment. The goal is to see if this approach can shrink tumors or stop them from growing. While not a cure, it offers a potential way to control the disease and manage symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Healthcare of Atlanta, Scottish Rite
Atlanta, Georgia, 30342, United States
-
Children's Healthcare of Atlanta-Egleston
Atlanta, Georgia, 30322, United States
-
Children's Mercy Hospital
Kansas City, Missouri, 64108, United States
-
Nemours/Alfred I. duPont Hospital for Children
Wilmington, Delaware, 19803, United States
-
Phoenix Children's Hospital
Phoenix, Arizona, 85016, United States
-
University of Virginia Health System
Charlottesville, Virginia, 22908, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Could sitting up make radiation therapy more comfortable?
- Can we predict dangerous side effects when combining radiation and immunotherapy?
- Can trained immune cells outsmart brain tumors?
- Family history as a shield: can culturally tailored guidance cut cancer risk?
- A simple screening program could transform cancer aftercare